Represents the royalty rate for combination products.

No definition available.

Name:	inva_CollaborativeArrangementAnnualRoyaltiesAsPercentageOfNetSalesForCombinationProducts
Namespace Prefix:	inva_
Data Type:	num:percentItemType
Balance Type:	na
Period Type:	duration

- Definition

Represents the royalty rate which the entity will receive under the collaboration agreement on the first defined level of annual global net sales.

+ References

No definition available.

+ Details

Name:	inva_CollaborativeArrangementRoyaltyRateDefinedLevelOne
Namespace Prefix:	inva_
Data Type:	num:percentItemType
Balance Type:	na
Period Type:	duration

- Definition

Represents the royalty rate which the entity will receive under the collaboration agreement on sales which exceed the first defined level of annual global net sales.

+ References

No definition available.

+ Details

Name:	inva_CollaborativeArrangementRoyaltyRateDefinedLevelTwo
Namespace Prefix:	inva_
Data Type:	num:percentItemType
Balance Type:	na
Period Type:	duration

- Definition

Represents the annual global net sales amount which determines the royalty rate applied under the collaboration arrangement.

+ References

No definition available.

+ Details

Name:	inva_CollaborativeArrangementSpecifiedSalesLevelForDeterminingRoyaltyRate
Namespace Prefix:	inva_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

Gross Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer before amortization of capitalized fees.

+ References

No definition available.

+ Details

Name:	inva_GrossRevenueFromContractWithCustomerExcludingAssessedTaxBeforeAmortizationOfCapitalizedFees
Namespace Prefix:	inva_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Represents the percentage of economic interest in any future payments made under the agreements.

+ References

No definition available.

+ Details

Name:	inva_PercentageOfEconomicInterestOnFuturePaymentsUnderAgreements
Namespace Prefix:	inva_
Data Type:	num:percentItemType
Balance Type:	na
Period Type:	duration

- Definition

Amount of amortization expense for asset recognized from cost incurred to obtain or fulfill contract with customer.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 340
-SubTopic 40
-Section 50
-Paragraph 3
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=68051541&loc=SL49131252-203054

+ Details

Name:	us-gaap_CapitalizedContractCostAmortization
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

Amount, before accumulated amortization and accumulated impairment loss, of asset recognized from cost incurred to obtain or fulfill contract with customer.

+ References

Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 340
-SubTopic 40
-Section 50
-Paragraph 3
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=68051541&loc=SL49131252-203054

+ Details

Name:	us-gaap_CapitalizedContractCostGross
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	instant

- Definition

Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.

+ References

No definition available.

+ Details

Name:	us-gaap_DisaggregationOfRevenueLineItems
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

- Definition

Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 4
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=118956577&loc=SL49130543-203045

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=118956577&loc=SL49130545-203045

+ Details

Name:	us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Details

Name:	srt_ProductOrServiceAxis=us-gaap_RoyaltyMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_ProductOrServiceAxis=inva_CollaborativeArrangementsMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=inva_GSKMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_ProductOrServiceAxis=inva_LongActingBeta2AgonistRelvarBreoMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_ProductOrServiceAxis=inva_LongActingBeta2AgonistAnoroMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_ProductOrServiceAxis=inva_TrelegyElliptaMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_TypeOfArrangementAxis=inva_StrategicAllianceAgreementMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_TypeOfArrangementAxis=inva_LabaCollaborationMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_RangeAxis=srt_MinimumMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_RangeAxis=srt_MaximumMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

REVENUE RECOGNITION AND COLLABORATIVE ARRANGEMENTS (Details) - USD ($) $ in Thousands	3 Months Ended								12 Months Ended
	Dec. 31, 2019	Sep. 30, 2019	Jun. 30, 2019	Mar. 31, 2019	Dec. 31, 2018	Sep. 30, 2018	Jun. 30, 2018	Mar. 31, 2018	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2014
Revenue Recognition and Collaborative Arrangements
Total net revenue	$ 75,971	$ 65,755	$ 64,107	$ 55,183	$ 79,858	$ 61,680	$ 67,086	$ 52,380	$ 261,016	$ 261,004	$ 217,217
Royalty revenue from a related party
Revenue Recognition and Collaborative Arrangements
Total net revenue									261,016	261,004	214,118
Revenue from collaborative arrangements from a related party
Revenue Recognition and Collaborative Arrangements
Total net revenue									0	0	3,099
GSK
Revenue Recognition and Collaborative Arrangements
Total net revenue									261,016	261,004	217,217
Milestone fees paid	$ 220,000				$ 220,000				220,000	220,000
GSK \| Royalty revenue from a related party
Revenue Recognition and Collaborative Arrangements
Royalties from a related party									274,839	274,827	227,941
Less: amortization of capitalized fees paid to a related party									(13,823)	(13,823)	(13,823)
Total net revenue									261,016	261,004	214,118
GSK \| RELVAR/BREO
Revenue Recognition and Collaborative Arrangements
Royalties from a related party									189,424	220,162	198,726
GSK \| ANORO
Revenue Recognition and Collaborative Arrangements
Royalties from a related party									42,625	41,286	29,036
GSK \| TRELEGY
Revenue Recognition and Collaborative Arrangements
Royalties from a related party									42,790	13,379	179
Strategic alliance - MABA program license \| GSK \| Revenue from collaborative arrangements from a related party
Revenue Recognition and Collaborative Arrangements
Total net revenue									$ 0	$ 0	$ 3,099
Long-Acting Beta2 Agonist (LABA) Collaboration \| GSK
Revenue Recognition and Collaborative Arrangements
Milestone fees paid												$ 220,000
Percentage of economic interest in any future payments made under the agreements									15.00%
Long-Acting Beta2 Agonist (LABA) Collaboration \| GSK \| RELVAR/BREO
Revenue Recognition and Collaborative Arrangements
Royalty rate for first level of annual global net sales (as a percent)									15.00%
Annual global sales level used to determine royalty rate									$ 3,000,000
Royalty rate for sales above first level of annual global net sales (as a percent)									5.00%
Long-Acting Beta2 Agonist (LABA) Collaboration \| GSK \| ANORO \| Minimum
Revenue Recognition and Collaborative Arrangements
Royalty rate for combination products (as a percent)									6.50%
Long-Acting Beta2 Agonist (LABA) Collaboration \| GSK \| ANORO \| Maximum
Revenue Recognition and Collaborative Arrangements
Royalty rate for combination products (as a percent)									10.00%
Long-Acting Beta2 Agonist (LABA) Collaboration \| GSK \| TRELEGY \| Minimum
Revenue Recognition and Collaborative Arrangements
Royalty rate for combination products (as a percent)									6.50%
Long-Acting Beta2 Agonist (LABA) Collaboration \| GSK \| TRELEGY \| Maximum
Revenue Recognition and Collaborative Arrangements
Royalty rate for combination products (as a percent)									10.00%